Trial of Therapeutic Hypothermia in Patients With ARDS
Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients With ARDS
University of Maryland, Baltimore
340 participants
Jun 29, 2021
INTERVENTIONAL
Conditions
Summary
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication of TH, often requiring paralysis with neuromuscular blocking agents (NMBA) to control. Since the recently completed NHLBI PETAL ROSE trial showed that NMBA had no effect (good or bad) in patients with moderate to severe ARDS, the CHILL trial is designed to evaluate whether TH combined with NMBA is beneficial in patients with ARDS. This Phase IIb randomized clinical trial is funded by the Department of Defense to compare TH (core temperature 34-35°C) + NMBA for 48h vs. usual temperature management in patients in 14 clinical centers with the Clinical Coordination Center and Data Coordinating Center at University of Maryland Baltimore. Planned enrollment is 340 over \~3.5 years of the 4-year contract. COVID-19 is considered an ARDS risk-factor and patients with ARDS secondary to COVID-19 pneumonia will be eligible for enrollment. Primary outcome is 28-day ventilator-free days. Secondary outcomes include safety, physiologic measures, mortality, hospital and ICU length of stay, and serum biomarkers collected at baseline and on days 1, 2, 3, 4, and 7.
Eligibility
Inclusion Criteria12
- endotracheal tube or tracheostomy in place and mechanically ventilated for ≤7 days;
- admitted to a participating ICU
- radiologic evidence of bilateral pulmonary infiltrates not fully explained by pleural effusions, atelectasis, or hydrostatic pulmonary edema
- P/F ratio ≤200 with PEEP ≥8 cm H2O; If ABG values are not available, the P/F ratio may be inferred from SpO2 values based on Table 3 from Brown et al as long as following conditions are met:
- SpO2 values are 80-96%
- SpO2 is measured ≥10 min after any change in FIO2
- PEEP is ≥ 8 cm H2O
- the pulse oximeter waveform tracing is adequate
- the qualifying inferred P/F ratio is confirmed 1-6h after initial determination.
- access to an LAR to provide consent.
- Criteria 3 AND 4 must be met within 72h of enrollment and randomization, not be fully explained by hydrostatic pulmonary edema, and must have occurred within 7 days of exposure to an ARDS-risk factor (including continuous exposure to persistent processes (e.g. sepsis, pneumonia, COVID-19).
- Patients may be enrolled and decision about randomization delayed if all criteria other than P/F ratio ≤ 200 are met and then randomized if and when the P/F ratio ≤200 (as long as this occurs within 72h of randomization). Patients on high flow nasal oxygen or non-invasive pressure ventilation may be consented if they meet criteria for starting the 72h ARDS window but may not be enrolled and randomized until they are intubated.
Exclusion Criteria28
- Missed moderate-severe ARDS window (>72hrs) - Window starts when patient is intubated with a qualifying P/F ratio of ≤ 200 with PEEP ≥ 8 cm H2O or on high flow nasal oxygen with well-fitting nasal cannula with flow ≥ 40 LPM and FiO2 ≥ 0.65 or on non-invasive pressure ventilation with PEEP ≥ 8 cm H2O and FiO2 ≥ 0.6.
- Missed NMB window: (>48 hrs)
- Missed mechanical ventilation window (>7 days)
- Refractory hypotension (continuous infusion of >0.3 mcg/kg/min of norepinephrine or equivalent dose of other vasopressors within 2 hours prior to randomization)
- Core temperature <35°C for ≥6 hours while not receiving CRRT on day of randomization
- Significant, active bleeding (>3u blood products and/or surgical/IR intervention) on day of randomization
- Platelets <10K/mm3 (uncorrected) on day of randomization
- Active hematologic malignancy and not expected to survive 6 months
- Skin process that precludes cooling device
- Moribund, not likely to survive 72h
- Pre-morbid condition makes it unlikely that patient will survive 28 days
- Do Not Resuscitate status at time of randomization (excluding patients receiving full support EXCEPT CPR for cardiac arrest)
- Not likely to remain intubated for ≥48h
- Physician of record unwilling to participate
- Severe underlying lung disease
- Needs > 2 LPM or >28% continuous home O2 (adjusted for altitude)
- On BIPAP (except for OSA)
- Prior lung transplantation
- Pregnant at time of randomization
- BMI consistently >50 kg/m2
- Known NYHA class IV heart disease
- Acute Coronary Syndrome (MI, unstable angina) within 30 days of randomization
- Cardiac arrest within 30 days of randomization with sequelae likely to increase mortality and/or time to ventilator liberation.
- Burns over >20% of the body surface
- Severe chronic liver disease (Child-Pugh score 12-15)
- Previously randomized in CHILL study
- Simultaneous enrollment in another inpatient interventional trial started during the current hospitalization.
- On ECMO during the current hospitalization.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04545424